Scarica l'app Stockscreener
21.43
5.55%
-1.26
Pre-mercato:
21.07
-0.36
-1.68%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Perché GMAB Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$22.69
Aprire:
$21.36
Volume 24 ore:
1.75M
Relative Volume:
1.27
Capitalizzazione di mercato:
$13.75B
Reddito:
$2.62B
Utile/perdita netta:
$966.70M
Rapporto P/E:
14.28
EPS:
1.5004
Flusso di cassa netto:
$1.09B
1 W Prestazione:
-1.61%
1M Prestazione:
+0.85%
6M Prestazione:
+12.79%
1 anno Prestazione:
-20.83%
Intervallo 1D:
$21.27
$21.66
Intervallo di 1 settimana:
$21.27
$22.89
Portata 52W:
$17.23
$27.94
Genmab Adr Stock (GMAB) Company Profile
Confronta GMAB con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
GMAB
Genmab Adr
|
21.43 | 13.23B | 2.62B | 966.70M | 1.09B | 1.5004 |
|
VRTX
Vertex Pharmaceuticals Inc
|
366.54 | 98.88B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.00 | 58.84B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
438.93 | 56.12B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
661.83 | 41.20B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.18 | 35.49B | 3.81B | -644.79M | -669.77M | -6.24 |
Genmab Adr Stock (GMAB) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-04-01 | Downgrade | Bernstein | Mkt Perform → Underperform |
| 2025-03-11 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2025-02-13 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2024-10-08 | Iniziato | Redburn Atlantic | Buy |
| 2024-09-04 | Ripresa | Morgan Stanley | Equal-Weight |
| 2024-08-20 | Downgrade | JP Morgan | Overweight → Neutral |
| 2024-07-15 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-02-23 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2024-01-22 | Downgrade | Citigroup | Neutral → Sell |
| 2023-12-06 | Aggiornamento | UBS | Neutral → Buy |
| 2023-11-10 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2023-11-08 | Aggiornamento | DNB Markets | Sell → Buy |
| 2023-10-18 | Iniziato | Exane BNP Paribas | Underperform |
| 2023-09-06 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-08-24 | Iniziato | BTIG Research | Buy |
| 2023-07-14 | Iniziato | HSBC Securities | Buy |
| 2023-05-31 | Iniziato | UBS | Neutral |
| 2023-05-12 | Iniziato | Morgan Stanley | Underweight |
| 2022-12-20 | Downgrade | Citigroup | Buy → Neutral |
| 2022-11-14 | Iniziato | William Blair | Mkt Perform |
| 2022-11-11 | Downgrade | Deutsche Bank | Buy → Hold |
| 2022-06-24 | Iniziato | BMO Capital Markets | Market Perform |
| 2022-05-02 | Iniziato | Cowen | Market Perform |
| 2022-03-16 | Aggiornamento | UBS | Neutral → Buy |
| 2022-01-31 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2022-01-03 | Downgrade | Guggenheim | Buy → Neutral |
| 2021-12-01 | Iniziato | Berenberg | Sell |
| 2021-09-16 | Downgrade | Jefferies | Buy → Hold |
| 2021-09-07 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2021-08-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2021-04-20 | Iniziato | Deutsche Bank | Buy |
| 2021-01-19 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-09-23 | Downgrade | Bryan Garnier | Neutral → Sell |
| 2020-09-08 | Iniziato | SVB Leerink | Mkt Perform |
| 2020-06-25 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2020-04-23 | Iniziato | Credit Suisse | Outperform |
| 2020-02-24 | Reiterato | H.C. Wainwright | Buy |
| 2020-01-13 | Iniziato | SunTrust | Buy |
| 2019-12-12 | Downgrade | Deutsche Bank | Buy → Hold |
| 2019-09-13 | Aggiornamento | BofA/Merrill | Neutral → Buy |
| 2019-09-12 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2019-08-12 | Iniziato | Guggenheim | Buy |
| 2019-08-12 | Iniziato | Morgan Stanley | Overweight |
| 2019-08-12 | Iniziato | RBC Capital Mkts | Outperform |
Mostra tutto
Genmab Adr Borsa (GMAB) Ultime notizie
What is William Blair’s Forecast for Genmab A/S Q3 Earnings? - Defense World
Genmab and BioNTech’s Innovative Cancer Trial: A Market Game Changer? - The Globe and Mail
Genmab and BioNTech’s GEN1042 Study: A Promising Step in Cancer Treatment - The Globe and Mail
BioNTech and Genmab’s Promising Colorectal Cancer Study: A Potential Game-Changer? - TipRanks
Wall Street Analysts Believe Genmab (GMAB) Could Rally 33.8%: Here's is How to Trade - Yahoo Finance
GMAB: Riding the Market Waves of Growth and Decline in 2025 - investchronicle.com
Genmab and BioNTech’s GEN1042 Study: A Potential Game-Changer in Cancer Treatment - TipRanks
Genmab and BioNTech’s Innovative Cancer Trial: A Potential Game-Changer? - The Globe and Mail
Genmab and BioNTech SE’s GEN1056 Study: A New Hope for Advanced Solid Tumors - TipRanks
Genmab A/S Sponsored ADR (NASDAQ:GMAB) Given Average Rating of “Moderate Buy” by Brokerages - Defense World
Genmab A/S Sponsored ADR (NASDAQ:GMAB) Stake Lessened by Cerity Partners LLC - Defense World
Genmab and BioNTech Launch Promising Study for Advanced Colorectal Cancer Treatment - The Globe and Mail
Genmab (GMAB) Upgraded to Strong Buy: Here's Why - MSN
Wall Street Analysts See a 39.97% Upside in Genmab (GMAB): Can the Stock Really Move This High? - Zacks Investment Research
Genmab A/S Sponsored ADR (NASDAQ:GMAB) Shares Purchased by Envestnet Asset Management Inc. - Defense World
Genmab Bets On Antibody Innovations As Royalties Rule The Day - Finimize
Genmab A/S FY2025 EPS Estimate Increased by William Blair - Defense World
Genmab AS (ADR) (US3723032062.SG) latest stock news and headlines - yahoo.co
Genmab A/S (NASDAQ:GMAB) Price Target Raised to $46.00 - Defense World
Genmab and BioNTech’s Promising Cancer Trial: A Potential Game-Changer? - TipRanks
Genmab and BioNTech’s GEN1042 Study: A New Hope for Cancer Treatment? - TipRanks
Genmab and BioNTech’s Pioneering Cancer Trial: A Potential Game-Changer? - The Globe and Mail
Genmab and BioNTech’s Promising Immunoradiotherapy Study for Metastatic Tumors - TipRanks
Genmab A/S Sponsored ADR (NASDAQ:GMAB) Receives Average Recommendation of “Moderate Buy” from Analysts - Defense World
Genmab and BioNTech’s GEN1056 Study: A Potential Game-Changer in Oncology - TipRanks
Mirae Asset Global Investments Co. Ltd. Cuts Stock Position in Genmab A/S Sponsored ADR (NASDAQ:GMAB) - Defense World
Envestnet Portfolio Solutions Inc. Sells 6,066 Shares of Genmab A/S Sponsored ADR (NASDAQ:GMAB) - Defense World
GAMMA Investing LLC Boosts Holdings in Genmab A/S Sponsored ADR (NASDAQ:GMAB) - Defense World
Genmab Announces Epcoritamab Investigational Combination Therapy Demonstrates High Response Rates in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Eligible for Autologous Stem Cell Transplantation (ASCT) - GlobeNewswire Inc.
Why Genmab Stock Smashed It On Monday - Barchart.com
Weekly Stock Grader Analysis: Upgrades & Downgrades on Top Blue-Chip Stocks - InvestorPlace
Applied Dna Sciences Inc (APDN)’s Day in Review: Closing at 0.85, Down by -2.41 - DWinneX
Stock Surge: Genmab ADR (GMAB) Closes at 19.42, Marking a -5.73 Increase/Decrease - DWinneX
Market Momentum Report: Evercore Inc (EVR)’s Positive Close at 216.74 - DWinneX
Investing in Take-Two Interactive Software, Inc (TTWO) Is Getting More Attractive - knoxdaily.com
Investing in Genmab ADR (GMAB): What You Must Know - knoxdaily.com
Nucor Corp (NUE) may enjoy gains as insiders got busy in the recent days - knoxdaily.com
EWTX Stock Sees Surge of Approximately 4.24% in Last Five Days - knoxdaily.com
GMAB or RGEN: Which Is the Better Value Stock Right Now? - Yahoo Finance
Should Value Investors Buy Genmab (GMAB) Stock? - Yahoo Finance
Genmab ADR (NASDAQ: GMAB) Jumps 1.19% In Recent Session. Here’s Everything You Need To Know. - Stocksregister
AGCO Corp (AGCO) Beta Value: Understanding the Market Risk - News Heater
Evercore Inc’s Mixed Bag: Down -29.24% in 6 Months, Down -20.22% in 30 Days - investchronicle.com
GMAB’s Debt-to-Equity Ratio at 0.03: What It Means for Genmab ADR’s Future - investchronicle.com
CZR Stock Sees Decline of Approximately -4.82% in Last Five Days - knoxdaily.com
Genmab gets European approval for cervical cancer treatment - medwatch.com
Magnite Inc (MGNI) may enjoy gains as insiders got busy in the recent days - knoxdaily.com
DLocal Limited (DLO) Shares Decline Despite Market Challenges - The News Heater
Genmab Adr Azioni (GMAB) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.24%
3.39%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):